THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • October 25th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
THIS AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT is entered into as of 22 December, 2009 (the “Amended and Restated Agreement”), between Oxford Immunotec Ltd (“OXFORD”), having its registered office at 94C Milton Park, Abingdon, Oxfordshire, OX14 4RY, United Kingdom and Statens Serum Institut (“SSI”), a governmental enterprise under the laws of the Kingdom of Denmark, with offices at 5, Artillerivej, 2300 Copenhagen S, Denmark.
A Supplement (hereinafter referred to as “Supplement”) to OXFORD-SSI Amended and Restated License and Supply Agreement (hereinafter re-ferred to as the “Agreement”). Background:A Supplement • October 25th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Whereas, SSI advised OXFORD that the opportunity to file a patent application directed towards the M.tuberculosis antigen TB12.3 would expire on October 1, 2010 and that SSI did not believe this antigen to be of importance within TB vac-cine production and/or TB diagnostic; and
